🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

Showing page 148 of 857 · Phase 3 first, then by program name

  1. Plegridy 125 micrograms solution for injection in pre-filled pen, AVONEX 30 micrograms/0.5ml solution for injection in pre-filled pen., Plegridy 63 micrograms+94 micrograms solution for injection in pre-filled pen, AVONEX 30 micrograms/0.5 ml solution for injection.

    Biogen

    Relapsing Remitting Multiple Sclerosis (RRMS)

    phase 3 small molecule active

    1 trial

  2. Plozasiran

    Arrowhead Pharmaceuticals Ireland Limited

    Familial Chylomicronemia

    phase 3 small molecule active

    1 trial

  3. Plozasiran

    Arrowhead Pharmaceuticals Ireland Limited

    Familial Chylomicronemia Syndrome

    phase 3 small molecule completed

    1 trial

  4. Plozasiran

    Arrowhead Pharmaceuticals Ireland Limited

    Severe Hypertriglyceridemia

    phase 3 small molecule active

    1 trial

  5. Plozasiran Injection

    Arrowhead Pharmaceuticals Ireland Limited

    Severe Hypertriglyceridemia

    phase 3 small molecule active

    2 trials

  6. Plozasiran Injection

    Arrowhead Pharmaceuticals Ireland Limited

    Hypertriglyceridemia

    phase 3 small molecule active

    2 trials

  7. Plozasiran Injection Placebo, ARO-APOC3 PFS

    Arrowhead Pharmaceuticals Ireland Limited

    Severe hypertriglyceridemia (SHTG)

    phase 3 small molecule active

    1 trial

  8. Plozasiran Injection Placebo, ARO-APOC3 PFS

    Arrowhead Pharmaceuticals Ireland Limited

    Severe hypertriglyceridemia (SHTG)

    phase 3 small molecule active

    1 trial

  9. Pneumovax® 23 solution for injection in pre-filled syringe Pneumococcal Polysaccharide Vaccine, V110, Pneumococcal 21-valent Conjugate Vaccine

    Merck Sharp and Dohme

    Pneumococcal disease

    phase 3 small molecule active

    1 trial

  10. Policosanol

    BRIGHT MINDS BIOSCIENCES INC.

    Hypercholesterolemia

    phase 3 small molecule terminated

    1 trial

  11. PolyCore

    Lacuna Pharma Pty Ltd

    Congestive Heart Failure

    phase 3 small molecule active

    1 trial

  12. Polyamide HD membrane

    Sionna Therapeutics

    End-stage Kidney Disease

    phase 3 other active

    1 trial

  13. Pomalidomide, Imnovid 3 mg hard capsules, Imnovid 1 mg hard capsules, Imnovid 2 mg hard capsules, Imnovid 4 mg hard capsules, Pomalidomide, Pomalidomide, DARZALEX 1800 mg solution for injection, Imnovid 3 mg hard capsules, BORTEZOMIB, Imnovid 2 mg hard capsules, FLUDARABINE , CARVYKTI 3.2 × 10^6 – 1.0 × 10^8 cells dispersion for infusion, Pomalidomide, Imnovid 4 mg hard capsules, Dexamethasone Tablets BP 2.0mg, Fortecortin® 2 mg Tabletten, Imnovid 1 mg hard capsules, CYCLOPHOSPHAMIDE , Dexamethason 4 mg JEN

    Janssen-Cilag International N.V.

    Relapsed and Lenalidomide-Refractory Multiple Myeloma

    phase 3 small molecule active

    1 trial

  14. Ponatinib

    Takeda

    Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)

    phase 3 small molecule active

    1 trial

  15. Ponatinib 30 mg QD

    Takeda

    Chronic Phase Chronic Myeloid Leukemia

    phase 3 small molecule terminated

    1 trial

  16. Ponesimod

    Vanda Pharmaceuticals Netherlands B.V.

    Moderate-to-severe Chronic Plaque Psoriasis

    phase 3 small molecule active

    1 trial

  17. Posterior Approach Compression Distraction Reduction

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Basilar Invagination Associated With Atlantoaxial Dislocation

    phase 3 other active

    1 trial

  18. Povetacicept

    Vertex Pharmaceuticals (Australia) Pty.

    Primary Membranous Nephropathy

    phase 3 small molecule active

    1 trial

  19. Povetacicept

    Vertex Pharmaceuticals (Australia) Pty.

    Immunoglobulin A Nephropathy

    phase 3 small molecule active

    1 trial

  20. Povorcitinib

    Incyte

    Hidradenitis Suppurativa (HS)

    phase 3 small molecule completed

    1 trial

  21. Povorcitinib, Placebo to Povorcitinib

    Incyte

    Vitiligo

    phase 3 small molecule active

    1 trial

  22. Povorcitinib, Placebo to Povorcitinib, Povorcitinib

    Incyte

    Prurigo Nodularis

    phase 3 small molecule active

    1 trial

  23. Povorcitinib, Povorcitinib

    Incyte

    Hidradenitis Suppurativa

    phase 3 small molecule active

    1 trial

  24. Povorcitinib, Povorcitinib, Povorcitinib

    Incyte

    Hidradenitis Suppurativa // Prurigo Nodularis // Vitiligo

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources